Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term prognosis. Found 35 abstracts

no pagination
Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MA, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol. 2020 Apr;203(4):684-9.
Li PD, Chen P, Peng X, Ma C, Zhang WJ, Dai XF. HOXC6 predicts invasion and poor survival in hepatocellular carcinoma by driving epithelial-mesenchymal transition. Aging. 2018 Jan 15;10(1):115-30.   PMCID: PMC5811246
Liu Z, Chen M, Xie LK, Liu T, Zou ZW, Li Y, Chen P, Peng X, Ma C, Zhang WJ, Li PD. CLCA4 inhibits cell proliferation and invasion of hepatocellular carcinoma by suppressing epithelial-mesenchymal transition via PI3K/AKT signaling. Aging. 2018 Oct 11;10(10):2570-84.   PMCID: PMC6224236
Mehrazin R, Dulaimi E, Uzzo RG, Devarjan K, Pei J, Smaldone MC, Kutikov A, Testa JR, Al-Saleem T. The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Therapeutic Advances in Urology. 2018 Jan;10(1):3-10.   PMCID: PMC5761913
Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Kogan DA, Alexander BM, Aizer AA. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study. Neuro-oncology. 2017 Oct 19;19(11):1511-21.   PMCID: PMC5737512
Liu T, Kan XF, Ma C, Chen LL, Cheng TT, Zou ZW, Li Y, Cao FJ, Zhang WJ, Yao J, Li PD. GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2017 Jun;39(6):1010428317700410.
Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM, Shah JP. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA: a cancer journal for clinicians. 2017 Mar;67(2):122-37.
Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM, Shah JP. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA: a cancer journal for clinicians. 2017 Jan 27;.
Cheng D, Zhao S, Tang H, Zhang D, Sun H, Yu F, Jiang W, Yue B, Wang J, Zhang M, Yu Y, Liu X, Sun X, Zhou Z, Qin X, Zhang X, Yan D, Wen Y, Peng Z. MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4. Oncotarget. 2016 Jul 19;7(29):45199-213.   PMCID: PMC5216716
Zhang Y, Xie J, Wang J, Yang D, Jiang Z, Han G, Fu Q, Zhang Y. Clinicopathological and Prognostic Analysis of Neuroendocrine Carcinoma of the Colorectum. Adv Clin Exp Med. 2016 Jul;25(4):719-24.
Zhao S, Tang H, Yan D, Fan J, Sun H, Wen Y, Yu F, Cui F, Zhang D, Xue Y, Liu C, Yue B, Chen J, Wang J, Wang X, Zhang M, Yu Y, Jiang W, Liu X, Mi Y, Zhou Z, Qin X, Peng Z. DDA1 promotes stage IIB-IIC colon cancer progression by activating NFkappaB/CSN2/GSK-3beta signaling. Oncotarget. 2016 Apr 12;7(15):19794-812.   PMCID: PMC4991419
Zijoo R, Olszanski AJ, Weinberg DS. Biomarkers and stage II colorectal cancer therapy. Translational Cancer Research. 2016 Jun;5:S84-S86.   PMCID: Editorial
Zhang Y, Wang J, Xie J, Yang D, Han G, Zhang Y, Fu Q. The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma. Eur Surg. 2015 Oct;47(5):248-53.
Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. Br J Haematol. 2014 Aug;166(4):514-20.
Mehrazin R, Smaldone MC, Kutikov A, Li T, Tomaszewski JJ, Canter DJ, Viterbo R, Greenberg RE, Chen DY, Uzzo RG. Growth kinetics and short-term outcomes of cT1b and cT2 renal masses under active surveillance. J Urol. 2014 Sep;192(3):659-64.   PMCID: 4419692
Husain H, Psyrri A, Markovic A, Rampias T, Pectasides E, Wang H, Slebos R, Yarbrough WG, Burtness B, Chung CH. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. The Laryngoscope. 2012 Dec;122(12):2762-8.   PMCID: PMC3574977
Sparano JA, Goldstein LJ, Davidson NE, Sledge GW, Gray R. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 2012 Jul;134(2):751-7.
Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2011 Apr;67(4):945-54.   PMCID: PMC3026871
Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. The oncologist. 2011 Dec;16(12):1675-83.   PMCID: not NIH funded
Rajput A, Romanus D, Weiser MR, Ter Veer A, Niland J, Wilson J, Skibber JM, Wong YN, Benson A, Earle CC, Schrag D. Meeting the 12 Lymph Node (LN) Benchmark in Colon Cancer. Journal of surgical oncology. 2010 Jul;102(1):3-9.   PMCID: not NIH funded
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term prognosis

prognosis Male Female Aged Middle Aged Adult pathology expression therapeutic use drug therapy mortality survival Neoplasm Staging genetics head and neck cancer depth of invasion staging Emt chemotherapy human papillomavirus-associated cancer hepatocellular carcinoma 80 and over Aged extranodal extension American Joint Committee on Cancer (AJCC) human papillomavirus (HPV) oropharynx administration & dosage Tumor Cell Line colon cancer renal cell carcinoma therapy Kidney Neoplasms Prospective Studies Antineoplastic Combined Chemotherapy Protocols colorectal neoplasms brain metastases Time Factors Seer renal cell carcinoma tamoxifen gene-expression c-MYC progression Tumor Burden Neoplasm Metastasis aggressiveness resection specimens breast-cancer 8q Dda1 Pi3k risk adverse effects Renal Cell Carcinoma akt interest marker follicular lymphoma Epithelial-Mesenchymal Transition Down-Regulation bladder-cancer Colorectal Neoplasms Antineoplastic Agents cancer MicroRNAs Pyrazines kinase Inflammatory breast cancer rectal-cancer diagnostic imaging 3' Untranslated Regions metabolism treatment basal-like subtype classification number watchful waiting Sunitinib adenocarcinoma progesterone-receptor Glycogen Synthase Kinase 3 beta epidemiology Survival Analysis Western Blotting HER-2 estrogen-receptor HCT116 Cells colorectal-carcinoma Disease Progression aneuploidy surgery oropharyngeal cancer Aurora A kinase MLN8054-Dose-limiting toxicity-Pharmacokinetics-Pharmacodynamics glutathione peroxidase 2 signature kidney neoplasms NF-kappa B tumor-development Local Neoplasm Recurrence centrosome amplification Bortezomib colon-cancer colorectal carcinoma Kinetics carcinomas Estrogen receptor Proportional Hazards Models cell lung-cancer tumor subtypes Smad4 Protein translocation colorectal cancer Nude Mice Follow-Up Studies Randomized Controlled Trials as Topic DNA-Binding Proteins ratio nuclear EGFR Head and neck squamous cell carcinoma-p16 Treatment Outcome drug effects Progesterone receptor methods Colonic Neoplasms Neoplastic Gene Expression Regulation local egfr Phase III Clinical Trials as Topic tumors Molecular subtypes cytogenetic analysis recurrence small-molecule inhibitor Smad4 Heterologous Transplantation Prognosis multicenter Fluorouracil lymph nodes Rituximab outcomes disease progression regulators phenotype Postoperative Period Sorafenib Clca4 Monoclonal Antibodies-Murine-Derived Watchful Waiting Adjuvant Chemotherapy
Last updated on Friday, August 07, 2020